LOS ANGELES, Apr 4: Investigators at Cedars-Sinai Health Sciences University have unveiled a series of groundbreaking studies spanning cardiac arrest prevention, cancer therapeutics, hypertension, gastrointestinal research, and advanced molecular analysis—highlighting the institution’s continued leadership in innovation-driven healthcare.
AI-Powered Algorithm Could Improve Access to Lifesaving AEDs
Researchers have developed a novel algorithm designed to optimize the placement of automated external defibrillators (AEDs), portable devices critical in treating sudden cardiac arrest. By analyzing incident data across Ventura County, California, and Multnomah County, Oregon (2012–2023), the algorithm identifies clusters of cardiac arrest cases and recommends AED placement within close proximity.
“Faster access to AEDs can significantly improve survival outcomes,” said Sumeet Chugh, senior author of the study. “This tool could help communities strategically position these lifesaving devices where they are needed most.”
The findings were published in IJC Heart & Vasculature, with further studies planned to validate the algorithm’s effectiveness in real-world settings.
Pharmacist-Led Care Reduces Readmissions in High-Risk Older Adults
A large multisite clinical trial involving over 6,000 patients found that older adults struggling with medication adherence were 10% less likely to be readmitted to the hospital when supported by pharmacist-led discharge care.
“This targeted intervention shows promise for patients who need it most,” said Joshua Pevnick, corresponding author of the study. “Improving medication understanding can meaningfully impact recovery outcomes.”
The study, published in JAMA Network Open, underscores the importance of personalized care strategies in improving post-discharge health.
New Drug Candidate Targets Key Proteins in Colon and Liver Cancer
Cedars-Sinai scientists have identified a promising compound that disrupts the interaction between two proteins—GIT1 and MAT2B—known to drive colorectal and liver cancer growth. The compound, known as C3, slows tumor progression and promotes cancer cell death in preclinical models.
“We’re excited about the potential of this dual-target approach,” said Shelly Lu, corresponding author. “This discovery could pave the way for more effective therapies across multiple cancer types.”
The study appears in Cell Death & Disease, with ongoing work focused on refining the compound for clinical application.
First-Ever Model of Functional Paneth Cells Created
In a major advancement for gastrointestinal research, Cedars-Sinai investigators have successfully developed human intestinal organoids containing functional Paneth cells—an achievement not previously accomplished.
“This model opens new pathways for studying diseases like Crohn’s,” said Robert Barrett, lead researcher. “It also holds promise for personalized medicine approaches using patient-derived cells.”
Published in Cellular and Molecular Gastroenterology and Hepatology, the study could accelerate research into immune-related gut disorders.
Genetic Insights Offer New Hope for Resistant Hypertension
A large-scale genetic study analyzing data from over 92,000 individuals has identified key variants linked to resistant hypertension—a condition affecting more than 10% of patients with high blood pressure.
“Pinpointing these genetic drivers allows for better diagnosis and targeted treatments,” said Joseph Ebinger. “This could ultimately reduce the risk of severe cardiovascular events.”
The findings, published in Hypertension, highlight the role of hormonal imbalance, particularly excess aldosterone, in difficult-to-control blood pressure.
Rapid ‘Multi-Omics’ Technique Could Transform Biomedical Research
Researchers have also introduced a cutting-edge analytical method—Single-Injection Multi-Omics Analysis by Direct Infusion (SMAD)—capable of identifying thousands of proteins and molecular features from a single sample in under five minutes.
“This technology can significantly accelerate drug discovery and biological research,” said Jesse Meyer, senior author of the study.
Detailed in Angewandte Chemie, the approach offers a faster, more cost-effective alternative to traditional molecular analysis workflows.
Driving the Future of Medicine
Collectively, these studies demonstrate Cedars-Sinai’s commitment to advancing precision medicine, improving patient outcomes, and accelerating the translation of research into real-world healthcare solutions.
From AI-powered tools and genetic insights to novel therapies and analytical technologies, Cedars-Sinai continues to shape the future of medicine through innovation and collaboration.
